TRIM16

TRIM16
Identifiers
AliasesTRIM16, EBBP, tripartite motif containing 16
External IDsOMIM: 609505; MGI: 2137356; HomoloGene: 4726; GeneCards: TRIM16; OMA:TRIM16 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

10626

94092

Ensembl

ENSG00000221926

ENSMUSG00000047821

UniProt

O95361

Q99PP9

RefSeq (mRNA)

NM_006470

NM_053169

RefSeq (protein)

NP_444399

Location (UCSC)n/aChr 11: 62.71 – 62.74 Mb
PubMed search[2][3]
Wikidata
View/Edit HumanView/Edit Mouse

Tripartite motif-containing protein 16 is a protein that in humans is encoded by the TRIM16 gene.[4][5]

This gene was identified as an estrogen and anti-estrogen regulated gene in epithelial cells stably expressing estrogen receptor. The protein encoded by this gene contains two B box domains and a coiled-coiled region that are characteristic of the B box zinc finger protein family.

The proteins of this family have been reported to be involved in a variety of biological processes including cell growth, differentiation and pathogenesis. Expression of this gene was detected in most tissues. Its function, however, has not yet been determined.[5]

Tripartite motif-containing protein 16, also known as TRIM16, is a protein encoded by the TRIM16 gene in humans. It is part of the TRIM family of proteins, characterized by one or two B-box domains and a coiled-coil region. Recent research showed that TRIM16 acts as an E3 ubiquitin ligase and molecular scaffold that participates in protein-quality control, tumor suppression, and protection against cardiac hypertrophy.[6][7][8] TRIM16 is expressed in many tissues and participates in cellular pathways that maintain proteostasis and regulate stress responses.[9]

Structure

The protein contains two B-box domains and a coiled-coil motif typical of the TRIM family, but lacks a canonical RING domain. These structural elements allow TRIM16 to mediate protein-protein interactions and to act as a ubiquitin-ligase adaptor. Early studies identified it as an estrogen-responsive gene in epithelial cells expressing the estrogen receptor, and expression has since been observed in most human tissues.[9]

The original identification of TRIM16, formerly known as EBBP, as an estrogen-regulated gene suggested that its expression[9] might be influenced by hormonal signals. Soon enough, investigators were able to determine that TRIM16 is highly expressed throughout a variety of tissues, such as heart, liver, lung, and skin.[9]

Function

TRIM16 has indeed been found to modulate both the formation and turnover of misfolded protein aggregates. Carroll et al., 2018, report that TRIM16 functions as an E3 ubiquitin ligase that bridges ubiquitinated substrates to autophagic receptors, integrating the sequestration of aggregation-prone proteins and stimulating their autophagic degradation.[6] In light of its two roles in the formation and removal of aggregates, TRIM16 may play a role in maintaining protein homeostasis under cellular stress.  

Further investigation revealed that TRIM16 is intimately associated with the p62-KEAP1-NRF2 pathway, a significant oxidative stress regulator. Usually, KEAP1 binds NRF2 and targets it for degradation, but under oxidative stress, TRIM16 disrupts this interaction and stabilizes NRF2, leading to the increased expression of antioxidant genes.[6] TRIM16 thus serves as a link between the antioxidant response and the protein-quality control system.

TRIM16 also acts as a platform for other autophagy-related proteins, including ULK1, ATG16L1, and LC3B, thereby facilitating the formation of autophagosomes responsible for the degradation of damaged proteins.[6]In this regard, TRIM16 helps cells cope with a proteotoxic environment by orchestrating protein aggregate formation and subsequent disassembly. Because TRIM16 can promote aggregate formation when conditions require it and then favor its subsequent degradation, this makes TRIM16 an exceptionally versatile component of the proteostasis network.

TRIM16 also interacts with transcription factor E2F1 and cytoskeletal protein vimentin, thus modulating cell-cycle progression and structural stability, and further extends its reach outside of stress regulation into the realm of general cell behavior.[7] 

Clinical significance

Tumor suppression

Moreover, TRIM16 safeguards the cardiovascular system. In neuroblastoma and other cancer models, TRIM16 can take on a tumor suppressive function. Marshall et al. 2010 demonstrated how TRIM16 suppresses cell migration and proliferation by interacting with the cytoskeletal protein vimentin and the transcription factor E2F1.[7]Such interactions reduce tumor growth and oncogenic signaling, thus providing evidence that loss in the activity of TRIM16 may facilitate cancer development.

Further study has identified that many aggressive cancers have reduced expression of TRIM16, which impairs the cell's ability to regulate cell proliferation and maintain structural integrity.[7] The tumor suppressor capabilities of TRIM16 were also supported by studies where forced expression of TRIM16 in tumor cells diminished growth and metastatic potential. TRIM16 also was associated with the retinoic acid signaling pathway, a differentiation pathway that can push cancer cells toward less malignant states.[9]

Cardiac hypertrophy

TRIM16 also has a protective function in the cardiovascular system. As Liu et al. (2021) established, TRIM16 restricts oxidative stress and cardiomyocyte hypertrophy by repressing pathological cardiac hypertrophy through the PRDX1-Nrf2 antioxidant pathway.[8] This finding broadens the physiological importance of TRIM16 from cell biology to whole-organ protection against stressful conditions.

The study in Circulation Research further showed that TRIM16 controls the activity of SRC kinase by labeling it for K48-linked ubiquintation, thereby decreasing SRC's contribution to hypertrophic signaling.[8] It further modulates the activity of PRDX1 to promote NRF2-HO-1 pathway activation and increase antioxidant capacity in cardiomyocytes.[8] This set of interactions protects the heart from oxidative damage and abnormal structural enlargement.

Overexpression of TRIM16 in mouse models prevented the development of more severe hypertrophy, increased fibrosis, and decreased heart function caused by TRIM16 loss. In addition, reduced TRIM16 levels were found in human hypertrophic heart samples, suggesting a potential diagnostic or therapeutic role. Integrative Significance Combined, the findings of the studies reported in the EMBO Journal [6]and Circulation Research[8] show that TRIM16 is at the interface of antioxidant control and proteostasis through cell cycle regulation to structural integrity.

References

  1. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000047821Ensembl, May 2017
  2. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  3. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, et al. (May 2001). "The tripartite motif family identifies cell compartments". The EMBO Journal. 20 (9): 2140–2151. doi:10.1093/emboj/20.9.2140. PMC 125245. PMID 11331580.
  5. ^ a b "Entrez Gene: TRIM16 tripartite motif-containing 16".
  6. ^ a b c d e Jena KK, Kolapalli SP, Mehto S, Nath P, Das B, Sahoo PK, et al. (September 2018). "TRIM16 controls assembly and degradation of protein aggregates by modulating the p62-NRF2 axis and autophagy". The EMBO Journal. 37 (18) e98358. doi:10.15252/embj.201798358. PMC 6138442. PMID 30143514.
  7. ^ a b c d Marshall GM, Bell JL, Koach J, Tan O, Kim P, Malyukova A, et al. (November 2010). "TRIM16 acts as a tumour suppressor by inhibitory effects on cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cells". Oncogene. 29 (46): 6172–6183. doi:10.1038/onc.2010.340. PMC 3007621. PMID 20729920.
  8. ^ a b c d e Liu J, Li W, Deng KQ, Tian S, Liu H, Shi H, et al. (May 2022). "The E3 Ligase TRIM16 Is a Key Suppressor of Pathological Cardiac Hypertrophy". Circulation Research. 130 (10): 1586–1600. doi:10.1161/CIRCRESAHA.121.318866. PMID 35437018.
  9. ^ a b c d e Liu HL, Golder-Novoselsky E, Seto MH, Webster L, McClary J, Zajchowski DA (November 1998). "The novel estrogen-responsive B-box protein (EBBP) gene is tamoxifen-regulated in cells expressing an estrogen receptor DNA-binding domain mutant". Molecular Endocrinology. 12 (11): 1733–1748. doi:10.1210/mend.12.11.0193. PMID 9817599.

Further reading